ArticleAnnals of hematology2025
Establishment of reference interval (RI) for G6PD/6PGD ratio in adults from Yangjiang, China.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aimed to explore reference interval (RI) for the determination of glucose-6-phosphate dehydrogenase (G6PD) deficiency in adults by means of G6PD/6PGD ratio assay. Given that G6PD/6PGD exhibits differences between male and female, the currently available RI of G6PD/6PGD is not applicable for screening G6PD deficiency in local population. This study investigates RI for the G6PD/6PGD in Yangjiang, providing valuable insights for clinical decision-making and treatment. A total of 5,186 individuals were included in this study, comprising 2,386 males and 2,800 females. G6PD/6PGD of these individuals was determined. G6PD genotypes and thalassemia genotypes of different groups were diagnosed, followed by relevant statistical analyses, and RI was determined using a non-parametric approach, defined by the 2.5th and 97.5th percentiles of the distribution. In Yangjiang, RI for G6PD/6PGD was 1.32-2.08 in male and 1.19-2.03 in female. The adjusted male median (AMM) and the normal male median (NMM) values were 1.68 and 1.69, respectively. Among the population with G6PD gene mutations, the upper limit of G6PD/6PGD RI was 0.5 for male. A 45% (G6PD/6PGD = 0.7605) threshold of the NMM could be used to estimate the probability of G6PD variants. When G6PD/6PGD was 0.7605, male had a variant-positivity rate of 97.39% and female was 92.31%. The G6PD/6PGD ratio measurements in this study enable more accurate assessment of G6PD activity levels in the Yangjiang population. These findings provide clinically relevant insights for optimizing treatment strategies and enhancing the prediction and management of G6PD deficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.